



SEQUENCE LISTING

<110> Quirk, Stephen
Tyrrell, David

<120> Design and Use of Advanced Zinc Chelating Peptides to Regulate Matrix Metalloproteinases

<130> 44039-227522 11301-0200

<140> US 09/753,139

<141> 2000-12-29

<160> 10

B'

<170> PatentIn version 3.1

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = Ser or Thr

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = Ser, Ala or Val

<400> 1

Cys Xaa Cys Xaa Pro His Pro
1 5

<210> 2

<211> 12

<212> PRT

<213> Artificial Sequence

*B1
Cont*
<220>

<223> Synthetic Peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X = Ile or Val

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = Glu, Gln or Arg

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = Phe or Tyr

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = Ile or Val

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> X = Tyr or His

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> X = Ala, Pro or Glu

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X = Pro, Phe or Ala

<220>

<221> MISC_FEATURE

B¹
cont

<222> (9)..(9)

<223> X = Ser, Asp or Met

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X = Ala or Ser

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> X = Val or Leu

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> X = Cys or Gly

<400> 2

Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

B1
Cont

<223> Synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X = Met, Val or Leu

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = His, Phe or Tyr

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = Ile or Thr

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = Thr, His or Gly

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> X = Leu or Thr

<220>

B1
Cont

<221> MISC_FEATURE

<222> (7)..(7)

<223> X = Asp, Asn or Ser

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X = Phe or Tyr

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> X = Ile or Val

<400> 3

Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 4

Cys Ser Ala Val Pro Val His
1 5

B1
cont

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 5

Asp Ser Ala Val Pro Val His
1 5

<210> 6

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 6

Ile Tyr Thr Ala Cys Met Ser Ala Val
1 5

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

B1
Cont

<400> 7

Val His Thr His Leu Cys Asp
1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 8

Cys Thr Cys Val Pro
1 5

<210> 9

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 9

Cys Asp Ile Cys
1

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 10

His Thr Ile Thr His

1

5
